Insider Selling: Immunome (NASDAQ:IMNM) Director Sells $1,633,892.93 in Stock

Key Points

• Immunome director Isaac Barchas sold 62,291 shares at an average price of $26.23, generating $1.63 million. The Rule 10b5-1 transaction reduced his direct holdings by 40.32% to 92,211 shares.
• Barchas has made multiple additional sales since late June, selling more than 300,000 shares in the transactions listed, while Immunome’s stock rose to $27.99—near its 52-week high of $28.04.
• Immunome reported a quarterly loss of $0.65 per share, missing the $0.51 consensus estimate. Despite the earnings miss, analysts maintain a “Moderate Buy” consensus with a $34.64 average price target.

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) Director Isaac Barchas sold 62,291 shares of Immunome stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $26.23, for a total transaction of $1,633,892.93. Following the completion of the sale, the director directly owned 92,211 shares of the company's stock, valued at approximately $2,418,694.53. The trade was a 40.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Wednesday, August 12th, Isaac Barchas sold 11,048 shares of Immunome stock. The stock was sold at an average price of $27.25, for a total transaction of $301,058.00.
• On Monday, August 10th, Isaac Barchas sold 10,125 shares of Immunome stock. The shares were sold at an average price of $26.07, for a total transaction of $263,958.75.
• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total transaction of $397,362.88.
• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total transaction of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The stock was sold at an average price of $24.20, for a total transaction of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total transaction of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total value of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Stock Performance

Shares of Immunome stock traded up $1.74 on Wednesday, hitting $27.99. The company had a trading volume of 1,561,300 shares, compared to its average volume of 1,383,354. The stock has a market capitalization of $3.17 billion, a price-to-earnings ratio of -11.76 and a beta of 2.07. Immunome, Inc. has a 1 year low of $8.66 and a 1 year high of $28.04. The stock has a 50 day moving average of $21.73 and a 200-day moving average of $22.18.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.14). Equities analysts anticipate that Immunome, Inc. will post -2.06 earnings per share for the current year.

Institutional Investors Weigh In On Immunome

Large investors have recently made changes to their positions in the business. Allworth Financial LP bought a new stake in shares of Immunome during the 2nd quarter worth $25,000. KBC Group NV bought a new stake in shares of Immunome in the 1st quarter worth approximately $60,000. BNP Paribas Financial Markets lifted its stake in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock valued at $60,000 after purchasing an additional 2,909 shares during the last quarter. Strs Ohio bought a new position in Immunome during the fourth quarter valued at $64,000. Finally, Tower Research Capital LLC TRC grew its holdings in Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock valued at $65,000 after purchasing an additional 3,802 shares during the period. 44.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IMNM has been the topic of a number of analyst reports. Citigroup reaffirmed a "buy" rating on shares of Immunome in a report on Thursday, July 9th. Leerink Partners lowered their target price on shares of Immunome from $37.00 to $33.00 and set an "outperform" rating for the company in a report on Friday, May 15th. Barclays initiated coverage on shares of Immunome in a research report on Thursday, May 28th. They set an "overweight" rating and a $36.00 price target on the stock. Truist Financial boosted their price target on shares of Immunome from $37.00 to $38.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Immunome in a research report on Thursday, July 9th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Immunome has a consensus rating of "Moderate Buy" and a consensus price target of $34.64.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source